Orexigen looking for FDA approval in next few months, says Cowen Cowen noted Orexigen announced Q4 results last night and provided an update on its regulatory processes. The firm remains positive on Contrave's potential lifecycle management opportunities and reiterates its Outperform rating and $10 price target.
Orexigen CEO says 'really pleased' with Contrave launch so far Narachi says "engaged deeply in conversations" with potential European partners for Contrave weight loss drug. Orexigen CEO Mike Narachi speaking on CNBC.
JPMorgan to hold a conference 33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link